NOVEMBER 2022


577


a)


b)


Fig 3: Grade 1 and grade 2 injection site reactions, respectively. Common objects were used as a size reference for reactions. Extent of reaction was traced with silver pen in order to document any change in shape or size of reaction


TABLE 2: Change in (a) complete blood count (CBC) and (b) serum biochemistry (SBP) data comparison pre- and post-study. All study participants had CBC and SBP values within the normal reference range prior to the start of study. Note: only values with statistically significant changes are reported (p < 0.05)


Mean change SD P-value


a. CBC Parameter Hgb (g/L)


Hgb cell (g/L) HCT (%)


RBC (106/uL) MCV (fl)


MCHC (g/L) CHCM (g/L)


Nucleated cells (103/uL)


Lymphocytes (103/uL)


b. SBP Parameter P (mMol/L) Ca (mMol/L) Mg (mMol/L) Glob (G/L) T-Bili (µMol L) SDH (IU/L) K (mEQ/L) Anion


(mMol/L)


-25.81 -27.20 -10.00 -1.52 -2.43 17.62 16.19 -1.95


-0.69 Basophils (103/uL) -0.09


0.42 -0.26 -0.18 4.09


Gap


22.46 2.04 -0.95 -1.48


Median Change


18.23 <0.0001 -30.00 16.64 <0.0001 -27.00 6.07 <0.0001 -11.00 0.92 <0.0001 -1.67 1.25 0.04


40 80


60


-2.00


1.04 <0.0001 2.00 8.65 0.0002 10.00 0.99 <0.0001 -2.00


0.46 0.0007 -0.70 0.09 0.0005 -0.10


0.42 0.0001 0.35 0.09 <0.0001 -0.28 0.11 <0.0001 -0.21 2.71 0.01


4.00


9.58 <0.0001 22.24 1.87 0.003


2.00


0.90 0.0004 -0.80 1.53 0.003 -2.00


pharmacodynamic effects as represented by differences in improvement and healing. In addition, these studies were performed in different horse populations with alternative management techniques and considering our understanding of the multifactorial nature of managing EGUS in horses, management factors may have contributed to the outcomes of the different LAO formulations. Improvement in ESGD was seen by Day 14 and did not


formulation (Sykes et al., 2017a). Another study showed a significant decrease in ESGD scoring of 0.03 to 0.51 grades following GG administration (Birkmann et al., 2014). It is recognised that the different LAO formulations studied utilise different long-acting vehicles, therefore may provide different pharmacokinetic profiles and may demonstrate different


significantly change from the Day 14 to 28, which may suggest that a shorter dosing scheme may adequately achieve clinical efficacy for ESGD. Previous findings in another study with a different LAO formulation also showed the most ESGD improvement by Day 14 (96%) with 100% improvement following 4 weeks of dosing (Rendle et al.,


© 2021 EVJ Ltd


20


0


0 12 24 36 48 60 72 84 96 108 120 132 144156 168 Time (h)


Fig 4: Box and whisker plot of serum omeprazole concentration per each sampled timepoint


[Omeprazole]serum (ng/ml)

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92